Mylan reached a $465 million settlement with the federal government over accusations it improperly classified EpiPens as a generic drug to overcharge Medicaid. Mylan was not required to admit any wrongdoing and the drugmaker does not have to classify EpiPens as a branded drug under Medicaid’s rebate program until April 2017.
Sen. Blumenthal believes Mylan should have to pay a much larger amount than $465 million, calling the settlement “a shadow of what it should be.” He wants the DOJ to conduct further investigation into Mylan’s actions, according to the report.
“[The settlement] short circuits an investigation and fact finding necessary to determine the scope of illegality, culpability of individuals and proof of criminal wrongdoing,” said Sen. Blumenthal writes in the letter. “Simply, this agreement is blatantly inadequate, notably in dollar amount, but also Mylan’s avoiding admission of moral and legal responsibility.”
More articles on supply chain:
Supply chain tip of the week: Use the 80/20 rule
Pfizer to launch biosimilar version of J&J’s Remicade in Nov.
Four key takeaways from the 2016 AHRMM Conference
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
